Jump to content

Biosafety Open Forum

Virtual Industry Workshop on NGS-Based Biosafety Testing, co-hosted by BMS

The aim of the second edition of this exclusive event is to bring together experts, to facilitate knowledge sharing, and industry discussions around the key challenges and opportunities in the fast-evolving area of biosafety testing.

We are delighted to announce that our host will be Dr. Anurag Khetan, Executive Director, Global Upstream and CLD, Biologics Development at Bristol-Myers Squibb. Anurag has over 20 years of industry experience in biologics R&D, having served in various positions at Merck, Biogen and Boehringer Ingelheim.

This invitation-only event is limited to industry participants and is free to attend.

Agenda

EDT

CEST

THURSDAY, SEPTEMBER 16th, 2021

9:00 am3:00 pmWelcome and Introduction to the Participants
Anurag Khetan, Executive Director, Global Upstream and CLD, Biologics Development at BMS
Thomas Hartsch, 
Head of Selector Business, Genedata
9:10 am3:10 pmSanofi Pasteur’s Strategy for Implementing HTS for Adventitious Virus Detection
Siemon Ng, Head of the Molecular Biology Centre at Sanofi Pasteur Analytical Science, Sanofi Pasteur
9:35 am3:35 pmDemo: NGS for Adventitious Agent Detection: Analysis Options and Consequences
Devon Ryan, Scientific Consultant, Genedata
9:55 am3:55 pmNGS-based Virus Safety Testing of Veterinary Master Seeds - Validation Data
Blandine de Saint-Vis, Global MSAT Bio-Analytics, Senior Scientist, Boehringer Ingelheim Animal Health
10:20 am4:20 pmPanel Discussion on Wet Lab, Bioinformatics and Regulatory Challenges
Siemon Ng, Head of the Molecular Biology Centre at Sanofi Pasteur Analytical Science, Sanofi Pasteur
Blandine de Saint-Vis, Global MSAT Bio-Analytics, Senior Scientist, Boehringer Ingelheim Animal Health
Veera Dheenadhayalan,
Director Biosafety at AstraZeneca

Moderated by Thomas Hartsch, Genedata
11:00 am5:00 pmEnd of Event

Attendees at the previous Genedata Selector Biosafety Open Forum included partners from

Disclaimer

“The purpose of our gathering and discussions is to start a pre-competitive R&D collaboration and discuss best practices using NGS-based biosafety to identify adventitious agents during biopharma R&D.  We consider our discussions to be pre-competitive in nature as the best practices can be used very broadly in the industry.  Please keep the conversation to this topic and refrain from bringing up topics that could be considered anti-competitive under antitrust/competition laws, such as pricing.”